Graft-versus-host disease (GvHD) is a complication of a bone marrow or stem cell transplant in which cells from a donor ...

People with severe symptoms of chronic graft versus host disease (GvHD) often need to use multiple treatments to manage their condition. In recent years, a new class of medicines known as kinase ...

Graft-versus-host disease (GVHD) is a major complication of bone marrow transplantation even among HLA-matched donors and recipients. It has been generally considered that the severity of GVHD is ...

The FDA has granted Mesoblast’s stem cell therapy, Ryoncil (remestemcel-L), seven years of orphan drug exclusivity for the ...

Graft vs. host disease (GVHD) can occur after a stem cell transplant from a donor. Transplants replace unhealthy cells with healthy blood-forming cells, which can treat some cancers. GVHD happens ...

PTCY is associated with lower rates of grade 2 to 4 acute GVHD but has delayed engraftment and increased graft failure. MUD transplants generally yield better outcomes than MMUD transplants, with PTCY ...

The regulator has cleared Ryoncil (remestemcel-L) to treat steroid-refractory acute GVHD in paediatric patients aged two months and older. It is derived from MSCs harvested from the bone marrow of ...

“Poor nutrition and poor body weight, as well as a loss of muscle mass, can increase the risk of developing GVHD,” says Michelle Bratton, RD, former nutrition educator with the LLS’s ...

Symptoms of graft versus host disease (GvHD) depend on the type you have and which parts of your body it affects. There are 2 main types of GVHD. They are: Acute GvHD generally happens within the ...

Gastrointestinal (GI) problems, liver dysfunction, skin rashes, and other symptoms can develop as acute (temporary) GVHD within 100 days of a transplant or as chronic GVHD months — or even years ...

The findings suggest dietary fiber could be a potential strategy to prevent GVHD, Jenny Paredes, PhD, staff scientist at City of Hope, and colleagues concluded. "We're not talking about a ...

The immunotherapy utilizes a mix of hematopoietic stem cells, purified T-regulatory cells, and reduced-dose conventional T cells to mitigate GVHD. Orca-T's reduced rehospitalization rates and ...